Related Experiment Videos

Apelin peptides block the entry of human immunodeficiency virus (HIV)

M X Zou1, H Y Liu, Y Haraguchi

  • 1Department of Molecular Physiology, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.

FEBS Letters
|May 10, 2000
PubMed

Insights

Apelin peptides inhibit human immunodeficiency virus (HIV) entry into brain cells by blocking the APJ receptor, a coreceptor for certain HIV strains. Apelin-36 showed the highest inhibitory efficiency.

Area of Science:

  • Virology
  • Cell Biology
  • G protein-coupled receptors

Background:

  • The orphan G protein-coupled receptor APJ functions as a coreceptor for human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV).
  • Certain HIV and SIV strains utilize APJ to infect brain-derived NP-2/CD4 cells, highlighting its role in viral entry into neural cells.

Purpose of the Study:

  • To investigate the potential of apelin peptides, endogenous ligands for APJ, to inhibit HIV infection.
  • To determine the efficacy of different apelin peptides in blocking HIV entry into APJ-expressing cells.

Main Methods:

  • Utilized NP-2/CD4 cells expressing the APJ receptor.
  • Assessed the inhibitory effects of various apelin peptides (apelin-36, apelin-17, apelin-13, apelin-12) on HIV-1 and HIV-2 infection.
  • Quantified viral entry into cells in the presence of apelin peptides.

Main Results:

  • Apelin peptides demonstrated inhibitory effects on the entry of specific HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ.
  • The inhibitory efficiency of the apelin peptides followed the order: apelin-36 > apelin-17 > apelin-13 > apelin-12.
  • Apelin-36 exhibited the strongest inhibition of HIV entry among the tested peptides.

Conclusions:

  • Apelin peptides can effectively inhibit the entry of certain HIV strains into cells via the APJ coreceptor.
  • Apelin-36 represents a potent inhibitor of HIV entry, suggesting potential therapeutic applications.
  • The findings underscore the role of the APJ receptor in HIV pathogenesis and offer a target for antiviral strategies.

Related Concept Videos